Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
NCT ID: NCT04625361
Last Updated: 2023-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
106 participants
INTERVENTIONAL
2021-01-20
2022-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease
NCT06175767
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
NCT05238701
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects
NCT06537050
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
NCT06189170
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers
NCT05844787
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single dose of HEC122505MsOH Tablets（pilot trial arm）
Healthy subjects receive single dose of tablets HEC122505MsOH
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 1）
Healthy subjects receive single dose of HEC122505MsOH or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 2）
Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 3,Fed/Fasting）
Following an overnight fast of at least 10 hours, a single dose of HEC585 will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 4）
Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Single dose of HEC122505MsOH Tablets（Part 1，Cohort 5）
Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Single dose of HEC122505MsOH Tablets（Part 1， Cohort 6）
Healthy subjects receive single dose of HEC122505MsOH tablets or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 1）
Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 2）
Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Multiple doses of HEC122505MsOH Tablets（Part 2， Cohort 3）
Healthy subjects receive multiple doses of HEC122505MsOH tablets or matching placebo
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HEC122505MsOH
Part2：Mulltiple doses once daily, up to 8 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Without Plann for pregnancy or pregnant within 3 months after enrollment throughout the trial.
3. Subjects aged between 18 and 45 (both inclusive) years old.
4. Healthy volunteers has a body weight ≥50 kg (for male) or ≥ 45kg (for female) and body mass index ≥18 and ≤28 kg/m2 at screening.
5. Subjects, who are healthy, as having no clinically significant abnormalities in vital signs, physical examination, clinical laboratory test results, Chest X-ray and 12-lead electrocardiogram (ECG).
Exclusion Criteria
2. Patients with the following diseases of clinical significance, including but not limited to those with gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases.
3. nown allergic reactions or hypersensitivity to any excipient of the drug formulation(s)， anaphylaxis physique.
4. Use of any prescription or non-prescription medications within 14 days prior to initial dosing，Use of any drugs that inhibit or induce liver metabolism within 28 days before the first dose, or use of any of the following drugs within 28 days before the first dose: monoamine oxidase inhibitors, opioids, serotonergic drugs, sympathetic nerves Drugs, breast cancer resistance protein substrates, dopaminergic antagonists, etc.
5. Consume foods or beverages containing caffeine, xanthine, alcohol, and grapefruit within 48 hours prior to initial dosing.
6. Positive results from urine drug screen test.
7. History of alcoholism or drink regularly within 3 months prior to the study (defined as Alcohol consumption of \> 21 units/week), or positive results from alcohol breath test.
8. Regular smoking of more than 10 cigarettes per day within 3 months before administration of study drug, or inability to refrain from smoking during the course of the study.
9. Donate blood or lose blood 400 mL or more within 1 month prior to initial dosing.
10. Subjects who plan to receive or have had organ transplants.
11. Females who are lactating/breastfeeding, or positive result from pregnancy test for women of child-bearing potential.
12. Subjects who participated in another clinical trial within 3 months prior to initial dosing.
13. Any other condition with in the opinion of the investigator would render the patient unsuitable for inclusion in the study.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sunshine Lake Pharma Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Xuhui Central Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEC122505-P-01/CRC-C2017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.